| PharmaEssentia |
Besremi (P1101) |
Approved in EU for treatment of Polycythemia Vera (PV); Apply for the FDA’s Coronavirus Treatment Acceleration Program |
| TaiGen Biotechnology |
Taigexyn® (Nemonoxacin) |
Approved new drug for treatment of drug-resistant bacterial infection in Taiwan and China; Treatment for recurrent pneumonia of COVID-19 patients. |
| GoldenBiotech |
Antroquinonol (Hocena) |
Phase II US IND-approved for mild and moderate COVID-19 patients |
| Senhwa Biosciences |
Silmitasertib (CX-4945) |
Phase II for cholangiocarcinoma in US, KR, TW; Named by QBI Coronavirus Research Group (QCRG) as Potential Covid-19 Therapy |
| Academia Sinica |
3C-like Protease Inhibitors |
Research (cell-based assay) |
| National Chung Hsing University (NCHU) |
5-benzyloxygramine |
Discovery |
| Mycenax |
LusiNEX (biosimilar of tocilizumab) |
FDA has approved a randomized phase III of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with pneumonia as a complication of COVID-19 |